Avery Kundrick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avery Kundrick has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Adam Margolius
Center for Neurological Restoration, Neurological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, United States
1 shared publication- Alfonso Fasano
Department of Biomedical Sciences Humanitas University Milan Italy
1 shared publication Benjamin Walter
Center for Neurological Restoration, Neurological Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, United States
1 shared publicationClaire Henchcliffe
Department of Neurology, University of California Irvine, Irvine, CA, USA
1 shared publicationClaire Sonneborn
Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publication- Drew S. Kern
University of Colorado Anschutz Medical Campus
1 shared publication
Latest Publications
- 1 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107848
Convention vs. innovation I: Skin biopsy for synuclein inclusions should now be used in the clinical setting
- 1 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107848
Convention vs. innovation I: Skin biopsy for synuclein inclusions should now be used in the clinical setting
- 1 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107849
Convention vs. innovation III: The promise of stem cell therapy in Parkinson's disease remains bright
- 1 May 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 136, 107849
Convention vs. innovation III: The promise of stem cell therapy in Parkinson's disease remains bright
- 22 March 2025
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-12
Therapeutic innovations for the symptomatic treatment of Parkinson’s disease: focus on technology-based therapies
As Parkinson’s disease (PD) progresses, patients experience motor fluctuations, which may manifest as motor and/or non-motor wearing off symptoms, delayed “ON” time, and/or levodopa-related dyskinesia. Deep brain stimulation (DBS) is an effective therapy but may not be suitable for all patients due to factors such as premorbid conditions age, or accessibility. We review technology-based therapeutic innovations for PD: infusion therapies and novel non-invasive neuromodulation methods using the following databases: PubMed, Cochrane, and Science Direct. Infusion therapies such as percutaneous (LCIG, LECIG) and subcutaneous options (ND0612, foslevodopa-foscarbidopa, CSAI) demonstrate significant benefits in reducing OFF time and enhancing ON time without troublesome dyskinesias. However, vigilance is required for procedural and skin adverse events. Neuromodulation approaches such as auricular, vagus nerve, and galvanic vestibular stimulation, as well as whole-body vibration, showed promising benefits in freezing of gait (FOG) and tremor. Infusion and non-invasive neuromodulation therapies provide additional treatment options for patients with refractory motor and non-motor symptoms and may be an alternative for those who experience limitations of traditional dopaminergic therapies and are not candidates for neurosurgical interventions.
- 22 March 2025
- Published by Springer Nature in Journal of Neural Transmission
- p. 1-12
Therapeutic innovations for the symptomatic treatment of Parkinson’s disease: focus on technology-based therapies
As Parkinson’s disease (PD) progresses, patients experience motor fluctuations, which may manifest as motor and/or non-motor wearing off symptoms, delayed “ON” time, and/or levodopa-related dyskinesia. Deep brain stimulation (DBS) is an effective therapy but may not be suitable for all patients due to factors such as premorbid conditions age, or accessibility. We review technology-based therapeutic innovations for PD: infusion therapies and novel non-invasive neuromodulation methods using the following databases: PubMed, Cochrane, and Science Direct. Infusion therapies such as percutaneous (LCIG, LECIG) and subcutaneous options (ND0612, foslevodopa-foscarbidopa, CSAI) demonstrate significant benefits in reducing OFF time and enhancing ON time without troublesome dyskinesias. However, vigilance is required for procedural and skin adverse events. Neuromodulation approaches such as auricular, vagus nerve, and galvanic vestibular stimulation, as well as whole-body vibration, showed promising benefits in freezing of gait (FOG) and tremor. Infusion and non-invasive neuromodulation therapies provide additional treatment options for patients with refractory motor and non-motor symptoms and may be an alternative for those who experience limitations of traditional dopaminergic therapies and are not candidates for neurosurgical interventions.
- 14 November 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 130, 107209
Dosing dilemma: Can reduced botulinum neurotoxin type-A doses offer longer-lasting effects in cervical dystonia?
- 14 November 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 130, 107209
Dosing dilemma: Can reduced botulinum neurotoxin type-A doses offer longer-lasting effects in cervical dystonia?
- Open Access
- 20 June 2023
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 9, 100206
Adopting a palliative care mindset is an unmet need in Parkinson’s disease
- 20 June 2023
- Published by Elsevier in Clinical Parkinsonism & Related Disorders
- Vol. 9, 100206
Open AccessAdopting a palliative care mindset is an unmet need in Parkinson’s disease